Upsher-Smith Laboratories, LLC

The US Food and Drug Administration’s newly revised stand on testosterone labeling for cardiovascular risk is the visible tip of the metaphorical iceberg of years of effort that went into evaluating a

Sawai Pharmaceutical has agreed to sell its Upsher-Smith Laboratories business to Taiwan’s Bora Pharmaceuticals in a deal worth up to $210m, bringing to an end a near seven-year sojourn in the US m

Sawai Pharmaceutical has agreed to sell its Upsher-Smith Laboratories business to Taiwan’s Bora Pharmaceuticals in a deal worth up to $210m, bringing to an end a near seven-year sojourn in the US m

The US Food and Drug Administration agreed to five modifications to the isotretinoin Risk Evaluation and Mitigation Strategy including a relaxation of pregnancy test procedures following an advisory